Lupus & antiphospholipid syndrome
Heterogeneity of antiphospholipid antibody profiles in a clinical cohort and association with distinct clinical features
Authors' conclusion
Distinct antiphospholipid antibody heterogeneity exists, categorisable into 'classical', 'inflammatory' and 'restricted' subtypes. This study identifies aPS/PT-IgM as a strong independent serological marker associated with clinical status.
Study context
- Population
- Patients with clinical features suggestive of antiphospholipid syndrome (APS) tested for criteria antibodies (lupus anticoagulant (LAC), aCL IgG/IgM, β2GPI IgG/IgM) and extended markers (aPS/PT IgG/IgM, aCL/β2GPI IgA)
- Participants
- 2,994 patients
- Outcome
- Antibody heterogeneity and diagnostic predictors of APS
Methodological detailsprincipal component analysis, multivariate logistic regression, ROC curve analysis
- Principal component analysis
- Multivariate logistic regression
- ROC curve analysis
Main finding
As reported in the abstract
- Principal component analysis (PCA): three dimensions explaining variance
- 73.56%
- PC1 (IgG/LAC axis)
- 41.42%
- PC2 (specific IgM axis)
- 18.12%
- PC3 (specific IgA axis)
- 14.02%
- aPS/PT-IgM as independent predictor of clinical diagnosis, aOR
- 1.147 (95% CI 1.129 to 1.165, p<0.001)
- AUC of aPS/PT-IgM for diagnosing triple-negative APS
- 0.868
Observational data: associations, not effects.
Original publication
Heterogeneity of antiphospholipid antibody profiles in a clinical cohort and association with distinct clinical features. RMD Open. Published 31 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →